INDV Stock Overview
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Indivior PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£9.25 |
52 Week High | UK£18.77 |
52 Week Low | UK£6.53 |
Beta | 0.18 |
11 Month Change | -6.28% |
3 Month Change | -35.22% |
1 Year Change | -47.26% |
33 Year Change | -3.09% |
5 Year Change | 182.79% |
Change since IPO | 23.33% |
Recent News & Updates
Recent updates
Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story
Aug 09Indivior PLC's (LON:INDV) Shares Not Telling The Full Story
May 29Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why
May 03We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Apr 10The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More
Feb 28Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?
Dec 11We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Oct 15We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Jun 27Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet
Mar 29Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly
Nov 24Indivior (LON:INDV) Seems To Use Debt Quite Sensibly
Jul 26Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet
Dec 11Shareholder Returns
INDV | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | -3.0% | 0.1% | -0.3% |
1Y | -47.3% | 20.4% | 11.6% |
Return vs Industry: INDV underperformed the UK Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: INDV underperformed the UK Market which returned 11.6% over the past year.
Price Volatility
INDV volatility | |
---|---|
INDV Average Weekly Movement | 12.6% |
Pharmaceuticals Industry Average Movement | 6.5% |
Market Average Movement | 4.6% |
10% most volatile stocks in GB Market | 9.7% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: INDV's share price has been volatile over the past 3 months.
Volatility Over Time: INDV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 1,000 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
Indivior PLC Fundamentals Summary
INDV fundamental statistics | |
---|---|
Market cap | UK£1.22b |
Earnings (TTM) | -UK£106.83m |
Revenue (TTM) | UK£869.02m |
1.4x
P/S Ratio-11.5x
P/E RatioIs INDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INDV income statement (TTM) | |
---|---|
Revenue | US$1.15b |
Cost of Revenue | US$236.00m |
Gross Profit | US$911.00m |
Other Expenses | US$1.05b |
Earnings | -US$141.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
Earnings per share (EPS) | -1.07 |
Gross Margin | 79.42% |
Net Profit Margin | -12.29% |
Debt/Equity Ratio | -196.7% |
How did INDV perform over the long term?
See historical performance and comparison